Your Personal Injury Lawyer in Dallas
Contact Us Today for the Representation You Deserve 469.757.4055

J&J unit to pay $181 million to settle Risperdal dispute

"Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes." Citing a Reuters story, the article said that "the payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients with Alzheimer's and dementia." While the drug is meant to treat schizophrenia, it is not approved for these conditions. The report also noted that "although it is legal for physicians to prescribe drugs such as Risperdal for unapproved indications, manufacturers are forbidden from promoting the drug to providers for such uses."